On February 5, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (liso-cel, BREYANZI, Bristol Myers Squibb), a chimeric antigen receptor (CAR) T cell therapy, for adult patients with certain types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have not responded to, or who have relapsed after, at least two other types of systemic treatment. This is the fourth CAR T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).
“People battling relapsed or refractory large B-cell lymphoma continue to face a challenging treatment journey, both physically and emotionally,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “lisocabtagene maraleucel is an innovative treatment that offers a new option for patients, and another reason for this community to maintain hope for the future.”
Update on CAR T Cell Therapy for Patients with Lymphoma Webinar
Tuesday, March 2, 2021 | 3:30 PM – 4:30 PM ET
Javier Munoz, MD, MS, FACP
Mayo Clinic, Arizona
Anne Beaven, MD
UNC Lineberger Comprehensive Cancer Center